Abstract
Ketamine can rapidly alleviate symptoms of treatment-resistant major depression within hours of a single administration. While this finding offers a new and promising trajectory for novel therapeutic development, identifying rapid antidepressant mechanisms of action have proven especially difficult. The goal of the current study was to investigate the cellular actions of (2R,6R)-hydroxynorketamine (HNK) – a metabolite of ketamine that has been shown preclinically to exert rapid antidepressant-like effects without dissociative-like properties and abuse potential.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
